semaj83/ctmatch_classification huggingface dataset:
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  High Risk of Developing Lung Cancer Smokers or former smokers At least 20 pack year history of smoking Ages 50  Had a CT scan of chest within last 24 months History of any cancer within 10 yrs (except skin cancer or cervical cancer) A serious illness that decreases life expectancy to less than 5 years Any current use of Oxygen Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Lung Cancer All patients aged above 21 years, capable of giving consent and suspected of lung cancer with radiological lung nodules and masses  Patients with contra-indications to bronchoscopy and CT-TTNA that active myocardial ischemia, uncorrected coagulopathy, severe respiratory distress, uncontrollable cough, and pregnancy will be excluded. Before females in the reproductive age are recruited, urine pregnancy test will be performed and confirmed negative
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Soft Tissue Sarcoma cases of undifferentiated sarcomas from ARST0332 (additional cases may be ascertained as eligible for this current project that also fall under ARST0332 to be requested later if necessary)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-small Cell Lung Cancer Metastasis From Other Cancers Histological confirmation of malignancy, unless the risks of biopsy are unacceptable and the lesion has grown on serial CT scan and/or is PET positive Eligible patients must have staging studies (e.g. chest radiograph, CT scan, MRI/CT Brain/Bone Scan) identifying them as patients with stage I or II, non-metastatic NSCLC (T1, N0, M0; T2, N0, M0; or T3, N0, M0 chest wall primary tumors only) patients with a non-lung primary that is controlled and which has metastasized to the lungs alone, in whom potentially curative surgery would otherwise be an option (e.g. colorectal, breast, sarcoma…etc) the subset of patients with limited (low) volume metastatic NSCLC or other primary site tumors whom it is felt may derive benefit from highdose SBRT treatment to the primary or metastatic lung tumor. And in whom other sites of metastatic disease are being treated with the desire to achieve long term control. Lesions must meet size in 4.1.2.1 Patients who have potentially resectable disease should be considered medically inoperable, or else in the judgement of the thoracic surgeon and lung team, surgery is not considered the preferred management option Early stage lung cancer: ≤3 parenchymal lung lesions, Metastatic disease to lungs: ≤5 parenchymal lung lesions Patients with early stage primary NSCLC should have hilar or mediastinal lymph nodes that are considered N0 on clinico-radiological grounds (i.e. no clinico-radiological evidence of lymph node spread) In patients with early stage primary NSCLC and a co-existing malignancy, the co-existing malignancy must have an expected prognosis better than primary lung lesion Adequate lung function to tolerate the planned stereotactic radiation  Patients with active systemic, pulmonary or pericardial infection No concurrent systemic therapy (chemotherapy, immunotherapy or biological therapy), apart from hormone therapy, is allowed History of active auto-immune diseases, including systemic lupus erythematous, rheumatoid arthritis, C.R.E.S.T., systemic sclerosis,scleroderma Potential candidate for concurrent chemo-radiation therapy Patient enrollment on other studies may be permissible. This will depend on patient and study characteristics
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer peripheral lung nodules < 3cm in size Surgical candidate  Non surgical candidate
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Multiple Sclerosis (MS) Must be between the ages of 18 and 45 years, inclusive Must have a body mass index (BMI) of 19 to 28 kilograms/height (m)2, inclusive, and have a minimum body weight of 50 kilograms (at screening and baseline) Must give written informed consent  History of severe allergic or anaphylactic reactions History of hypersensitivity to acetaminophen (paracetamol) or ibuprofen. Subjects in Part III of the study will also be excluded for history of hypersensitivity to human albumin History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease History of asthma, as defined by wheezing, dyspnea, or cough requiring treatment with either inhaled beta-2-agonists, inhaled corticosteroids, inhaled cromolyn sodium, or oral steroids or history of chronic obstructive pulmonary disease (including chronic bronchitis, bronchiectasis, or emphysema) Abnormal screening full pulmonary function tests (PFTs) or baseline spirometry (predicted values are those of the European Coal and Steel Community (Quanjer, 1983)) or abnormal screening or baseline oximetry, as defined by any one of the following <80% predicted Forced expiratory volume (FEV1) <80% predicted forced vital capacity (FVC) <70% FEV1/FVC ratio <80% predicted total lung capacity (TLC) <80% predicted diffusion capacity, corrected for hemoglobin (DLCOcorr)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Melanoma At least 18 years of age Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's Regional Ethics Board/Independent Ethics Committee (REB/IEC) Histologically documented cutaneous or mucosal malignant melanoma, which is recurrent or metastatic and is not curable by surgical or other means Adequate tumour tissue (greater than 0.5cm3 preferred, 3 X core biopsy acceptable) available and agreement from subjects that this tissue from their primary and/or metastatic tumour be made available for assessment of potential biomarkers Ability and availability to complete all prescribed biomarker studies (Screening and after Cycle 2) Recovered to Grade 1 from reversible toxicities of prior therapy Presence of clinically and/or radiologically documented disease. At least one site of disease (which will not be removed during the course of the study) must be uni-dimensionally measurable as per 1.1 or clinically quantifiable (such as in the case of skin disease) ECOG performance status of 0 Prior treatment with any number of immunotherapies (e.g., IL2, ipilimumab), targeted therapies (e.g., vemurafenib) are permitted but no more than one 1 prior chemotherapy Acceptable liver function  Anticancer treatment with radiation therapy, targeted therapies, chemotherapy, immunotherapy, hormones or other antitumour therapies within 28 days prior to first dose of TH-302 Subjects who have received any other investigational drug or agent within 28 days of first dose of TH-302 Current use of drugs with known cardiotoxicity Significant cardiac dysfunction Seizure disorders requiring anticonvulsant therapy Progressing brain metastases (unless previously treated and stable disease for a period of greater than or equal to 3 months on repeat MRI following definitive treatment) History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for greater than 2 years Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation less than 90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause hypoxia of normal tissue Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Emphysema Chronic Obstructive Pulmonary Disease (COPD) Willing and able to provide informed consent and to participate in the study Age > or = 40 years at the time of the screening Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan Minimum of 2 subsegments appropriate for treatment MRCD questionnaire score of 2 or greater at screening Failure of medical therapy to provide relief of symptoms Spirometry 15 minutes after administration of bronchodilator (BOTH) FEV1 < 50 % predicted FEV1/FVC ratio <70 % Lung volumes by plethysmography (BOTH)  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, or prior lung transplantation Requirement for ventilator support (invasive or non-invasive) Three (3) or more COPD exacerbations requiring hospitalization within 1 year of Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of Screening visit Pulmonary hypertension, defined as Echocardiogram with estimated peak systolic pressure > 45 mmHg in the presence of tricuspid valve regurgitation stated in the echocardiogram report If the echocardiogram shows peak systolic pressure > 45 mmHg, right heart catheterization is required to rule out pulmonary hypertension, defined as peak systolic pressure > 45 mmHg or mean pressure > 35 mmHg Clinically significant asthma (reversible airway obstruction) or bronchiectasis CT scan: Presence of the following radiologic abnormalities Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if present for 2 years or more without increase in size or if proven benign by biopsy/PET) Radiologic picture consistent with active pulmonary infection, e.g., unexplained parenchymal infiltrate
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Solid Tumour Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment Evaluable tumour deposits by one or more techniques (X-ray, CT, MRI, ultrasound) Age 18 years or older Life expectancy of at least three months Patients had to give written informed consent (which must be consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) and local legislation) Eastern Cooperative Oncology Group (ECOG) performance score < 2 Full recovery from all therapy-related toxicities from previous chemo-, hormone-,immuno-, or radiotherapy  History of relevant surgical procedures during the last four weeks prior to treatment with the trial drug, or active ulcers, or injuries with incomplete wound healing Pregnancy or breastfeeding Active infectious disease Brain metastases requiring therapy Absolute neutrophil count less than 1500 / mm3 Platelet count less than 100 000 / mm3 Bilirubin greater than 1.5 mg / dl (> 26 μmol / L, International System of Units (SI unit) equivalent) Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal) Serum creatinine greater than 1.5 mg / dl (> 132 μmol / L, SI unit equivalent) Uncontrolled, severe hypertension
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Neoplasm of Lung A soft tissue solitary dominant pulmonary nodule of ≥ 8mm and ≤30mm on axial plane Measured on lung window using conventional CT scan No other ancillary evidence strongly indicative of malignancy (e.g. distant metastases or unequivocal local invasion) If clinicians and reporting radiologists believe the patient is being treated as having a single pulmonary nodule and there are other small lesions <4mm that would normally be disregarded, the patient should be included in the trial Nodules already under surveillance can be included provided they have a recent or scheduled FDG-PET/CT18 years of age or over at time of providing consent Able and willing to consent to study  Pregnancy History of malignancy within the past 2 years Confirmed aetiology of the nodule at the time of qualifying CT scan As this is a diagnostic study, should the aetiology of the nodule be confirmed by investigation such as FDG-PET/CT or bronchoscopy prior to consent the patient remains eligible as the intention to is made on the analysis of the qualifying CT scan Biopsy of nodule prior to DCE-CT scan Contra-indication to potential radiotherapy or surgery Contra indication to scans (assessed by local procedures)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  PROSTATE CANCER Treatment naïve group Men with no prior diagnosis of prostate cancer undergoing prostate biopsy based on identified lesions on imaging Men with a raised PSA above 15ng/ml Men giving informed consent Treated men Men undergoing tissue biopsy for suspicion of prostate cancer recurrence following previous local or systemic therapy based on identified lesions in multi-parametric MRI, bone-scan, choline PET/CT, or PET/MRI  Unable to have MRI scan or CT scan, or in whom artefact would reduce scan quality Unable to have prostate biopsy Unable to undergo biopsy for metastatic evaluation On immunosuppression or predefined immunosuppressed state A coagulopathy predisposing to bleeding Unable to give informed consent
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solitary Pulmonary Nodule Bronchial Neoplasms age over 18 years Planed thoracoscopic surgery of a pulmonary nodule Informed consent  mental incapacity contraindications for this treatment pregnancy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Squamous Cell Carcinoma of the Anus Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus Age ≥18 years ECOG Performance status ≤2 Measurable disease according to Response Evaluation in Solid Tumours (RECIST) version 1.1 Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus HIV+ patients will be considered eligible with a CD4 count of ≥200 Adequate cardiac and respiratory function; absolute neutrophil count (ANC) ≥1.5x10^9/l; white blood cell (WBC) count ≥3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) ≥9g/dl; creatinine clearance >50ml/minute; serum bilirubin ≤1.5x upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5x ULN; alkaline phosphatase (ALP) ≤3x ULN Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy Life expectancy of at least 3 months  Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease Surgery or palliative radiotherapy within 28 days of randomisation Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome (naso-gastric or jejunostomy feeding tube is permitted) Acute hepatitis C and/or chronic active hepatitis B infection Serious active infection requiring i.v. antibiotics at enrolment
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Respiratory Distress Syndrome (ARDS) intubation and mechanical ventilation in the ICU Ramsay score 6 under sedation and analgesia ICU respirator implemented with pressure-volume curve device age equal to or greater than 18 years ARDS defined from the Berlin absence of pneumothorax on the CXR before the study Absence of pleural effusion greater than 500 ml estimated from ultrasonography no child-bearing woman written inform consent signed by the next of kin  Pneumothorax Pleural effusion greater than 500 ml estimated from ultrasonography Thoracic surgery in the last 3 months Contra-indication to CXR contra-indication to PEEP of 15 cm H2O contra-indication to PEEP of 15 or PEEP 15 mandated pressure-volume curve not feasible refusal to participate language barrier of the next of kin child-bearing woman
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Subjects of all races and ethnic origins over 18 years of age will be recruited Patients must have suspicious or known to be malignant solitary pulmonary nodule,5cm or less in size  Patients with a contraindication to MRI examinations will be excluded from this study Contraindications to MRI examinations Medically unstable Heart failure Unstable angina Child bearing Lactating Not a surgical candidate Any contraindication per MRI Screening Form (Appendix A attached). This is the same form used in clinical practice at UT Southwestern Titanium implants, pacemakers
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Stroke Upper Extremity Paresis age between 18-90 years old hemisyndrome (central paralysis of the upper extremity, and all degrees of weakness: M0 M5 on the paresis scale) as a result of a first stroke sub-acute lesion not more than 6 weeks post ictus  insufficient state of consciousness severe aphasia severe cognitive deficits severe pathologies of the upper extremity of traumatic or rheumatic nature severe pain in the affected arm Patients with pacemakers and other active implants
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Video-assisted Thoracoscopic Surgery (VATS) One-lung Ventilation signed informed consent elective left video-assisted thoracoscopy one lung ventilation  Anticipated difficult mask ventilation or intubation tracheal or high bronchial origin of the right upper lobe main bronchus severe COPD or asthma pleural disease previous left thoracic surgery chest radiotherapy chimiotherapy significant systemic co-morbidity active or chronic pulmonary infection fibrosis, other interstitial diseases